Addex Therapeutics Ltd (ADXN) P/E Ratio History
Historical price-to-earnings valuation from 2024 to 2025
Loading P/E history...
ADXN Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Addex Therapeutics Ltd (ADXN) trades at a price-to-earnings ratio of 0.7x, with a stock price of $7.01 and trailing twelve-month earnings per share of $-6.49.
The current P/E is 49% below its 5-year average of 1.3x. Over the past five years, ADXN's P/E has ranged from a low of 0.7x to a high of 2.0x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, ADXN trades at a 97% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, ADXN trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ADXN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ADXN P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 9.9 | - | +68% | |
| $2B | 6.9Lowest | 0.67Best | +817%Best | |
| $15B | 32.0 | 13.69 | +42% | |
| $921B | 42.5 | 1.47 | +96% | |
| $151B | 19.5 | - | -4% | |
| $358B | 85.5 | - | -1% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
ADXN Historical P/E Data (2024–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $7.34 | $10.44 | 0.7x | -45% |
| FY2024 Q4 | $7.00 | $8.44 | 0.8x | -35% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $9.77 | $6.32 | 1.5x | +22% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $8.22 | $4.13 | 2.0x | +57% |
Average P/E for displayed period: 1.3x
See ADXN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ADXN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ADXN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonADXN — Frequently Asked Questions
Quick answers to the most common questions about buying ADXN stock.
Is ADXN stock overvalued or undervalued?
ADXN trades at 0.7x P/E, below its 5-year average of 1.3x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does ADXN's valuation compare to peers?
Addex Therapeutics Ltd P/E of 0.7x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is ADXN's PEG ratio?
ADXN PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2024-2025.